Cabaletta Bio, Inc.
CABAHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cabaletta Bio, Inc. (CABA) is listed under Biotechnology. At a $249.2M market cap, Cabaletta Bio, Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Market Cap
$249.2M
Beta
3.48
P/E (TTM)
—
P/E (Fwd)
-1.24
EPS (TTM)
$-1.46
EPS (Fwd)
$-1.19
ROE
-93.2%
ROA
-48.2%
Cash
$225.1M
Total Debt
$25.7M
Free CF
-$98.3M
52W Change
-40.5%
Annual Financials
Cash vs Debt
Where CABA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CABA finished 49.32% below its 150-day moving average ($2.92) and 48.61% below its 200-day moving average ($2.88). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CABA overbought or oversold?
At the October 20, 2026 close, CABA's RSI(14) was 25.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cabaletta Bio, Inc. holds $225.1M in cash against $25.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$98.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -93.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Cabaletta Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, CABA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cabaletta Bio, Inc. and its sector.